Silihan lan utang jangka dawa perusahaan Relmada (RLMD)

Relmada Therapeutics (RLMD) adheres to ESG principles, ensuring ethical trials and environmentally sustainable production. The business is based on the development of REL-1017, an innovative fast-acting antidepressant. This trading chart demonstrates long-term debt, which currently stands at 0.00. Growth prospects rely on potential licensing deals with industry behemoths, as the current M&A strategy has been temporarily suspended.

This indicator measures total long-term liabilities, determining the balance between financial stability and the availability of resources for operational development. By analyzing the current level of the firm's long-term borrowings, an investor can assess the liquidity shortage risk for Relmada Therapeutics (RLMD), which is critical given the dependence on a single drug, REL-1017, and high clinical trial costs amid fierce competition.